Enlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19
August 02, 2023 08:00 ET
|
Enlivex Therapeutics Ltd
Data published in Frontiers in Immunology show a robust safety profile and rapid resolution from ARDS and parallel resolution of inflammation markers and elevated cytokines/chemokines, as well as...
Results of Annual General Meeting and General Meeting
June 14, 2023 08:30 ET
|
Biodexa Pharmaceuticals PLC
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Results of Annual General Meeting and General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a...
GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 15, 2023 17:00 ET
|
GT Biopharma, Inc.
Cash of approximately $19.9 million as of March 31, 2023, provides ample runway to fund operations into Q2 2024; anticipated to be sufficient to achieve IND clearance for GTB-3650 and GTB-5550, and...
GT Biopharma Names Charles J. Casamento to the Board of Directors
May 04, 2023 09:05 ET
|
GT Biopharma, Inc.
BRISBANE, CALIFORNIA, May 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based...
Bioxytran Interview at the Emerging Growth Conference
May 01, 2023 08:00 ET
|
BIOXYTRAN, INC.
Wednesday, May 3, 2023 12:35 pm –1:05 pm ESTMedical/Scientific Community Reaction to Peer Reviewed Article BOSTON, MASSACHUSETTS, May 01, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT)...
QSAM Biosciences Receives Second Key Patent in Europe for its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam®
April 26, 2023 08:00 ET
|
QSAM Biosciences Inc.
Austin, TX, April 26, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
60 Degrees Pharmaceuticals Awarded U.S. Patent Covering Tafenoquine for Treatment of COVID-19 and Other Lung Infections
April 26, 2023 07:34 ET
|
Sixty Degrees Pharmaceuticals
Patent provides exclusive use through 2040 of tafenoquine for treatment of COVID-19 and other lung infections. Tafenoquine is the active molecule in 60P’s FDA-approved drug for malaria prevention,...
IMUNON Presents Poster at the American Association for Cancer Research Annual Meeting Demonstrating Preclinical Immune Response of IMNN-001
April 19, 2023 08:30 ET
|
Imunon, Inc.
Findings from a mouse model of peritoneally disseminated ovarian cancer suggest biweekly dosing regimen for further evaluation in human clinical studies LAWRENCEVILLE, N.J., April 19, 2023 (GLOBE...
IMUNON Reports 2022 Financial Results and Provides Business Update
March 30, 2023 08:00 ET
|
Imunon, Inc.
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused...
Bioxytran Announces Positive Phase 2 Trial Results were Featured in “Vaccines” a Peer-Reviewed Journal
March 29, 2023 07:00 ET
|
BIOXYTRAN, INC.
Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001)Complete elimination of most symptoms by day 7 Galectin antagonist acts as an entry inhibitor for use in...